Stock Events

Stock Events

Agios Pharmaceuticals 

$33.10
46
-$0.03-0.09% 20:00 Today
+$0.00+0%20:17After hours

Statistics

Day High
33.45
Day Low
33.04
52W High
46
52W Low
22.24
Volume
20,074
Avg. Volume
-
Mkt Cap
1.98B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.95
-1.71
-1.46
-1.21
Expected EPS
-1.214415
Actual EPS
N/A

Financials

-764.01%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
54.03MRevenue
-412.78MNet Income

Analyst Ratings

41.43Average Price Target
The highest estimate is 55.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
57%
Hold
43%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGIO. It's not an investment recommendation.
Abbvie
10
ABBV
NVIDIA
9
NVDA
Microsoft
8
MSFT
Alphabet
8
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Agios's approach to treating genetic diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, competing in the rare disease market space.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad portfolio including oncology, competing in the cancer treatment space where Agios is also active.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for cancer and cardiovascular disease, areas Agios is exploring.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical specializes in enzyme replacement therapies for rare genetic disorders, directly competing with Agios's focus areas.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a wide range of healthcare solutions, including treatments for cancer and rare diseases, overlapping with Agios's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics for rare genetic diseases, competing in the same niche as Agios.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics specializes in precision genetic medicines using base editing, a novel approach that competes with Agios's strategies.

About

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Show more...
CEO
Brian Goff
Employees
540
Country
United States
ISIN
US00847X1046
WKN
000A1W2RM

Listings

STU
DE
8AP.STU
MU
DE
8AP.MU
F
DE
8AP.F
LSE
GB
0HB0.LSE

0 Comments

Share your thoughts

FAQ

What is Agios Pharmaceuticals stock price today?▼
The current price of AGIO is $33.10 USD — it has decreased by -0.09% in the past 24 hours. Watch Agios Pharmaceuticals stock price performance more closely on the chart.
What is Agios Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Agios Pharmaceuticals stocks are traded under the ticker AGIO.
Is Agios Pharmaceuticals stock price growing?▼
AGIO stock has fallen by -0.66% compared to the previous week, the month change is a +4.75% rise, over the last year Agios Pharmaceuticals has showed a -8.39% decrease.
What is Agios Pharmaceuticals market cap?▼
Today Agios Pharmaceuticals has the market capitalization of 1.98B
When is the next Agios Pharmaceuticals earnings date?▼
Agios Pharmaceuticals is going to release the next earnings report on October 29, 2026.
What were Agios Pharmaceuticals earnings last quarter?▼
AGIO earnings for the last quarter are -1.69 USD per share, whereas the estimation was -1.65 USD resulting in a -2.13% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Agios Pharmaceuticals revenue for the last year?▼
Agios Pharmaceuticals revenue for the last year amounts to 54.03M USD.
What is Agios Pharmaceuticals net income for the last year?▼
AGIO net income for the last year is -412.78M USD.
How many employees does Agios Pharmaceuticals have?▼
As of September 04, 2026, the company has 540 employees.
In which sector is Agios Pharmaceuticals located?▼
Agios Pharmaceuticals operates in the Health & Wellness sector.
When did Agios Pharmaceuticals complete a stock split?▼
Agios Pharmaceuticals has not had any recent stock splits.
Where is Agios Pharmaceuticals headquartered?▼
Agios Pharmaceuticals is headquartered in CAMBRIDGE, United States.